The European Union indicated on Monday 20 April that it had updated its regulatory adaptations to COVID-19, in particular with regard to good manufacturing practices (GMP) and safety checks. Regulatory flexibility is among the demands of the pharmaceutical industry, as evidenced by a webinar organised on the same day by the pharmaceutical industry lobby, EFPIA.
Regulatory framework opportunities activated
On 10 April, the Commission, the European Medicines Agency (EMA) and the Directors of...